https://globenewswire.com/news-release/2018/03/27/1453547/0/en/Krystal-Submits-Investigational-New-Drug-IND-Application-for-KB103-Topical-Gene-Therapy-Candidate-for-Dystrophic-Epidermolysis-Bullosa.html
This topic was automatically closed 14 days after the last reply. New replies are no longer allowed.